MedTrace Logo

Photobiomodulation for Concussions: the Use of the ImPACT® Test as an Assessment Tool

NCT04823507 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2021-04-01

No results posted yet for this study

Summary

Brain photobiomodulation (PBM) therapy is an innovative modality for the stimulation of neural activity in order to improve brain function and is currently under investigation as a treatment for several diverse neurological disorders. Our emphasis on this study is to review the use of PBM as a treatment modality for concussions and the use of ImPACT® (Immediate Post-Concussion Assessment and Cognitive Testing) test to assess improvement in cognition and symptomatology in patients with post-concussion syndrome (PCS) treated with PBM.

Conditions

  • Mild Traumatic Brain Injury

Interventions

DEVICE

BIOFLEX DUO+

* Data scores will be collected for patients who initially underwent the Workplace Post-Injury 1 test of the ImPACT® test system prior to PBM treatment. * Patients were treated with photobiomodulation using the BIOFLEX® DUO+ system that utilized a 180 bulb Light Emitting Diode (LED) array followed by laser probes. Both delivery methods were applied to the cervical spine and the cranium, and both entailed the use of red light at 660 nm wavelength and near-infrared light at 830-840 nm wavelength. Treatment is provided three times per week on alternating days with weekends off for 4 weeks for a total of 12 treatments utilizing Health Canada approved device specific protocol guidelines for treatment of the cervical spine. * Data scores will be collected for a second ImPACT® test using the Workplace Post-Injury 2 test. * Results of the Post-Injury 1 test and the Post-Injury 2 test will be compared.

Sponsors & Collaborators

  • Meditech Rehabilitation Centre

    lead OTHER

Principal Investigators

  • Michael Zitney, MD · Meditech Rehabilitation Centre

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-26
Primary Completion
2021-03-29
Completion
2021-03-29
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04823507 on ClinicalTrials.gov